Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/48853
Title: Accessibility and safety of antipsychotics in the treatment of autism spectrum disorder in children and adolescents
Authors: Sadaf, Shaista
Mifsud Buhagiar, Luana
Attard Pizzuto, Maresca
Serracino-Inglott, Anthony
Keywords: Autism spectrum disorders -- Treatment
Risperidone
Aripiprazole
Autism spectrum disorders -- Malta -- Case studies
Autism spectrum disorders -- India -- Case studies
Autism spectrum disorders -- Comparative studies
Childhood Autism Rating Scale
Antipsychotic drugs
Issue Date: 2018-10
Publisher: University of Malta. Department of Pharmacy
Citation: Sadaf, S., Mifsud Buhagiar, L., Attard Pizzuto, M., & Serracino-Inglott, A. (2018, October). Accessibility and safety of antipsychotics in the treatment of autism spectrum disorder in children and adolescents. Poster session presented at the ACCP Global Conference on Clinical Pharmacy, Seattle, Washington, USA.
Abstract: A poster presentation regarding the accessibility and safety of antipsychotics in the treatment of autism spectrum disorder in children and adolescents. Introduction: Risperidone and aripiprazole (RiAr) are antipsychotic drugs approved by the Food and Drug Administration (FDA) for the management of irritability associated with Autism Spectrum Disorder (ASD) in children and adolescents. Cultural, regulatory and economic differences in countries like India and Malta may affect the prescribing behaviour of these drugs in ASD. Aims: To study prescribing behaviour, safety and accessibility of RiAr in children and adolescents in India and Malta.
URI: https://www.um.edu.mt/library/oar/handle/123456789/48853
Appears in Collections:Scholarly Works - FacM&SPha



Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.